News Column

Reports Summarize Graft-Versus-Host Disease Study Results from University of Liege (Comprehensive plasma profiling for the characterization of...

July 9, 2014

Reports Summarize Graft-Versus-Host Disease Study Results from University of Liege (Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Immune System Diseases and Conditions have been published. According to news reporting originating from Liege, Belgium, by NewsRx correspondents, research stated, "Acute graft-versus-host disease (aGVHD) remains a life-threatening complication of hematopoietic stem cell transplantation (HSCT) therefore limiting its application. To optimize the management of aGVHD and reduce therapy-related toxicity, early specific markers are needed."

Our news editors obtained a quote from the research from the University of Liege, "The main objective of this study was to uncover diagnostic biomarkers by comparing plasma protein profiles of patients at the time of acute GVHD diagnosis with those of patients undergoing HSCT without aGVHD. Additional analysis of samples taken 15 days before aGVHD diagnosis was also performed to evaluate the potential of our newly discovered biomarkers for early diagnosis. To get complementary information from plasma samples, we used three different proteomic approaches, namely 2D-DIGE, SELDI-TOF-MS and 2D-LC-MSE. We identified and confirmed by the means of independent techniques, the differential expression of several proteins indicating significantly increased inflammation response and disturbance in the coagulation cascade. The variation of these proteins was already observed 15 days before GVHD diagnosis, suggesting the potential early detection of the disease before symptoms appearance. Finally, logistic regression analysis determined a composite biomarker panel comprising fibrinogen, fragment of fibrinogen beta chain, SAA, prothrombin fragments, apolipoprotein A1 and hepcidin that optimally discriminated patients with and without GVHD."

According to the news editors, the research concluded: "The area under the receiver operating characteristic curve distinguishing these 2 groups was 0.95."

For more information on this research see: Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers. Talanta, 2014;125():265-275. Talanta can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier -; Talanta -

The news editors report that additional information may be obtained by contacting M. De Bock, University of Liege, CHU, Inst Pharm, CIRMDept Pharmaceut Analyt Chem, B-4000 Liege, Belgium. Additional authors for this research include Y. Beguin, P. Leprince, E. Willems, F. Baron, C. Deroyer, L. Seidel, E. Cavalier, D. de Seny, M. Malaise, A. Gothot, M.P. Merville and M. Fillet (see also Immune System Diseases and Conditions).

Keywords for this news article include: Liege, Europe, Belgium, Graft-Versus-Host Disease, Immune System Diseases and Conditions

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters